Recovered heart failure with reduced ejection fraction and outcomes: a prospective study

European Journal of Heart Failure

Volumn 19, Issue 12, 2017, Pages 1615-1623

  Lupón, Josep ^a,b,c   Díez López, Carles ^a   de Antonio, Marta ^a   Domingo, Mar ^a   Zamora, Elisabet ^a,b   Moliner, Pedro ^a   González, Beatriz ^a   Santesmases, Javier ^a   Troya, Maria I ^a   Bayés Genís, Antoni ^a,b,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Heart failure with mid range ejection fraction; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction; Left ventricular ejection fraction; Recovered

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; IVABRADINE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST;

ADULT; AGE; AGED; AMYLOIDOSIS; ARTICLE; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE DURATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART FAILURE RECOVERED; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEW YORK HEART ASSOCIATION CLASS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SUDDEN DEATH; TACHYCARDIA; CONVALESCENCE; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; MIDDLE AGED; MORTALITY; PHYSIOLOGY; RISK FACTOR; SPAIN; SURVIVAL RATE; TIME FACTOR; TRENDS;

AGED; CAUSE OF DEATH; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART VENTRICLES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RISK FACTORS; SPAIN; STROKE VOLUME; SURVIVAL RATE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 85017332749     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.824     Document Type: Article

References (22)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–869.
2. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–2467.
3. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781.
4. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392.
5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
6. Hellawell J, Margulies KB. Myocardial reverse remodeling. Cardiovasc Ther 2012;30:172–181.
7. Punnoose LR, Givertz MM, Lewis EF, Pratibhu P, Stevenson LW, Desai AS. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail 2011;17:527–532.
8. Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 2014;129:2380–2387.
9. Teeter WA, Thibodeau JT, Rao K, Brickner ME, Toto KH, Nelson LL, Mishkin JD, Ayers CR, Miller JG, Mammen PP, Patel PC, Markham DW, Drazner MH. The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation. Am Heart J 2012;164:358–364.
10. Cioffi G, Stefenelli C, Tarantini L, Opasich C. Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. J Card Fail 2004;10:250–257.
11. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamogsatham S, Patel A, Li S, Papadimitriou L, Butler J. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 2016;1:510–518.
12. de Groote P, Fertin M, Duva Pentiah A, Goéminne C, Lamblin N, Bauters C. Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after β-blocker therapy. Circ Heart Fail 2014;7:434–439.
13. Stevenson LW. Heart failure with better ejection fraction. A modern diagnosis. Circulation 2014;129:2364–2367.
14. Zamora E, Lupón J, Vila J, Urrutia A, de Antonio M, Sanz H, Grau M, Ara J, Bayés-Genís A. Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, Chronic Kidney Disease Epidemiology Collaboration, and Cockroft-Gault formulas. J Am Coll Cardiol 2012;59:1709–1715.
15. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011;57:1468–1476.
16. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
17. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
18. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, Roger VL. Hospitalizations after heart failure diagnosis: a community perspective. J Am Coll Cardiol 2009;54:1695–1702.
19. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015;36:1990–1997.
20. Basuray A, Fang JC. Management of patients with recovered systolic function. Prog Cardiovasc Dis 2016;58:434–443.
21. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart. Myth, magic, or molecular target? J Am Coll Cardiol 2012;60:2465–2472.
22. Nadruz W Jr, West E, Santos M, Skali H, Groarke JD, Forman DE, Shah AM. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail 2016;9:e002826.